Skip to main content

Table 2 Exposure cohort restrictions and right-censoring criteria

From: The necessity of validity diagnostics when drawing causal inferences from observational data: lessons from a multi-database evaluation of the risk of non-infectious uveitis among patients exposed to Remicade®

Indication

Cohort type

Exposures

Restrictions

Right-censoring criteria*

Irritable bowel diseases (Crohn’s disease or ulcerative colitis)

Target

Remicade®

-TNFαi1 except infliximab

-infliximab biosimilars

-interleukin inhibitors2

-vedolizumab

-natalizumab

-adalimumab

-certolizumab pegol

-etanercept

-golimumab

-vedolizumab

-natalizumab

-interleukin inhibitors2

Irritable bowel diseases (Crohn’s disease or ulcerative colitis)

Comparator

golimumab, certolizumab pegol, ustekinumab, or vedolizumab

-TNFαi1 except certolizumab pegol and golimumab

-natalizumab

-infliximab

-adalimumab

-etanercept

-natalizumab

-interleukin inhibitors2 except ustekinumab

Ankylosing spondylitis

Target

Remicade®

-TNFαi1 except infliximab

-infliximab biosimilars

-interleukin inhibitors2

-adalimumab

-etanercept

-golimumab

-certolizumab pegol

-interleukin inhibitors2

Ankylosing spondylitis

Comparator

golimumab, certolizumab pegol, ixekizumab, or secukinumab

-TNFαi1 except certolizumab pegol and golimumab

-interleukin inhibitors2

-infliximab

-adalimumab

-etanercept

-interleukin inhibitors2 except ixekizumab and secukinumab

Plaque psoriasis or psoriatic arthritis

Target

Remicade®

-TNFαi1 except infliximab

-infliximab biosimilars

-interleukin inhibitors2

-adalimumab

-etanercept

-certolizumab pegol

-golimumab

-interleukin inhibitors2

Plaque psoriasis or psoriatic arthritis

Comparator

golimumab, certolizumab pegol, guselkumab, risankizumab, tildrakizumab, brodalumab, ixekizumab, secukinumab, or ustekinumab

-infliximab

-adalimumab

-certolizumab pegol

-etanercept

-golimumab

-Interleukin inhibitors2

-infliximab

-adalimumab

-etanercept

-interleukin inhibitors2 except brodalumab, guselkumab, ixekizumab, Risankizumab, secukinumab, tildrakizumab and ustekinumab

Rheumatoid Arthritis

Target

Remicade® & Methotrexate*

-TNFαi1

-interleukin inhibitors2

-abatacept

-adalimumab

-certolizumab pegol

-etanercept

-golimumab

-abatacept

-interleukin inhibitors2

Rheumatoid Arthritis

Comparator

certolizumab pegol or tocilizumab

-TNFαi1

-interleukin inhibitors2

-abatacept

-infliximab

-adalimumab

-etanercept

-golimumab

-abatacept

-interleukin inhibitors2 except tocilizumab

  1. Key: TNFαi: tumor necrosis factor α inhibitors
  2. *Right-censoring criteria for all exposure cohorts includes exposure discontinuation and database discontinuation
  3. 1: adalimumab, certolizumab pegol, etanercept, golimumab, infliximab
  4. 2: anakinra, basiliximab, brodalumab, canakinumab, daclizumab, guselkumab, ixekizumab, rilonacept, risankizumab, sarilumab, sarilumab, secukinumab, siltuximab, tildrakizumab, tocilizumab, ustekinumab
Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us